Subscribe to our Newsletters !!
How are viruses different from bacteria apex ? O
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
French drugmaker Sanofi and its British peer GSK have begun a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical firms race to develop treatments against the coronavirus pandemic. Sanofi and GSK said in a joint statement on Thursday they’d begun the”Stage 1/2″ trial for their adjuvanted COVID-19 vaccine, and that they expect to make available across the world. This vaccine candidate utilizes the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines with GSK’s recognized pandemic adjuvant technology.
